国药一致
(000028)
| 流通市值：167.84亿 | | | 总市值：195.41亿 |
| 流通股本：4.78亿 | | | 总股本：5.57亿 |
| 报告期 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 19,090,480,767.9 | 75,477,484,620.31 | 56,585,864,462.43 | 38,387,531,548.02 |
| 营业收入 | 19,090,480,767.9 | 75,477,484,620.31 | 56,585,864,462.43 | 38,387,531,548.02 |
| 二、营业总成本 | 18,628,475,913.31 | 73,277,097,009.14 | 54,981,233,258.64 | 37,247,256,783.78 |
| 营业成本 | 17,017,096,958.66 | 66,425,425,560.97 | 50,047,171,308.75 | 33,936,795,493.63 |
| 税金及附加 | 45,477,310.67 | 188,179,527.25 | 139,146,072.06 | 90,565,798.82 |
| 销售费用 | 1,262,401,329.62 | 5,325,952,104.74 | 3,843,549,409.41 | 2,603,399,550.61 |
| 管理费用 | 251,652,163.09 | 1,106,183,600.91 | 809,305,753.41 | 530,700,423.37 |
| 研发费用 | 6,260,235.43 | 26,821,075.48 | 17,958,532.28 | 12,036,610.44 |
| 财务费用 | 45,587,915.84 | 204,535,139.79 | 124,102,182.73 | 73,758,906.91 |
| 其中:利息费用 | 54,746,969.73 | 248,381,403.74 | 183,512,340.27 | 108,243,264.84 |
| 其中:利息收入 | 19,236,371.74 | 77,554,162.67 | 59,403,654.73 | 40,116,689.23 |
| 加:公允价值变动收益 | - | -15,161,078.05 | 17,429,083.72 | 17,429,083.72 |
| 加:投资收益 | 102,737,216.42 | 237,029,425.25 | 227,062,900.14 | 155,665,779.3 |
| 资产处置收益 | 3,007,708.24 | 45,308,289.49 | 10,779,728.41 | 8,040,031.01 |
| 资产减值损失(新) | -1,812,728.91 | -17,577,127.43 | -8,649,604.5 | -2,531,696.1 |
| 信用减值损失(新) | -40,849,138.51 | -76,999,197.73 | -87,284,674.42 | -61,686,822.23 |
| 其他收益 | 18,913,224.65 | 94,437,236.84 | 58,954,583.16 | 37,922,093.37 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 544,001,136.48 | 2,467,425,159.54 | 1,822,923,220.3 | 1,295,113,233.31 |
| 加:营业外收入 | 8,150,689.76 | 24,452,663.64 | 9,139,642.63 | 5,925,619.41 |
| 减:营业外支出 | 1,902,524.11 | 18,651,278.23 | 11,610,008.98 | 9,384,511.19 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 550,249,302.13 | 2,473,226,544.95 | 1,820,452,853.95 | 1,291,654,341.53 |
| 减:所得税费用 | 104,126,239.11 | 514,739,444.25 | 370,257,970.77 | 262,248,826.39 |
| 六、净利润 | 446,123,063.02 | 1,958,487,100.7 | 1,450,194,883.18 | 1,029,405,515.14 |
| 持续经营净利润 | 446,123,063.02 | 1,958,487,100.7 | 1,450,194,883.18 | 1,029,405,515.14 |
| 归属于母公司股东的净利润 | 388,770,710.07 | 1,599,255,755.53 | 1,189,663,637.63 | 830,251,088.2 |
| 少数股东损益 | 57,352,352.95 | 359,231,345.17 | 260,531,245.55 | 199,154,426.94 |
| (一)基本每股收益 | 0.7 | 2.87 | 2.14 | 1.49 |
| (二)稀释每股收益 | 0.7 | 2.87 | 2.14 | 1.49 |
| 八、其他综合收益 | - | 56,309.63 | -9,845.92 | -9,845.92 |
| 归属于母公司股东的其他综合收益 | - | 38,049.25 | -9,845.92 | -9,845.92 |
| 九、综合收益总额 | 446,123,063.02 | 1,958,543,410.33 | 1,450,185,037.26 | 1,029,395,669.22 |
| 归属于母公司股东的综合收益总额 | 388,770,710.07 | 1,599,293,804.78 | 1,189,653,791.71 | 830,241,242.28 |
| 归属于少数股东的综合收益总额 | 57,352,352.95 | 359,249,605.55 | 260,531,245.55 | 199,154,426.94 |
| 公告日期 | 2024-04-26 | 2024-04-08 | 2023-10-27 | 2023-08-29 |
| 审计意见(境内) | | 标准无保留意见 | | |